13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q2 2025. See the latest, Q2 2026 →

Reported value

$2.14B

+35% on the quarter before

Positions

1 new · 5 sold out

Top 10

89.6%

of the value

Est. gain

+$593.0M

on stocks held all quarter

Est. return

+38.5%

on those stocks since Q1 2025

Filed

Aug 1, 2025

On SEC EDGAR ↗

Positions as of Jun 30, 2025, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2025. Striped tiles are options.

Ast Spacemobile Inc20%

Arm Holdings Plc15%

Freshworks Inc11%

Planet Labs Pbc9.1%

Revolution Medicines Inc7.1%

Metsera Inc6.6%

Verve Therapeutics Inc6.4%

Gitlab Inc5.8%

Tempus AI4.6%

Dexcom Inc4.2%

UiPath4.2%

Prime Medicine Inc1.7%

Maze Therapeutics Inc1.4%

0.5%

Ast Spacemobile Inc20%

Arm Holdings Plc15%

Freshworks Inc11%

Planet Labs Pbc9.1%

Revolution Medicines Inc7.1%

Metsera Inc6.6%

Verve Therapeutics Inc6.4%

Gitlab Inc5.8%

Tempus AI4.6%

Dexcom Inc4.2%

UiPath4.2%

Prime Medicine Inc1.7%

Maze Therapeutics Inc1.4%

0.5%

Largest buys

Since Q1 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Lyell Immunopharma Inc~$2.6MNew · 0.0% → 0.1%+293,256 shares

Largest sells

Since Q1 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

CrowdStrike~$26.2MSold out · 1.7% → 0.0%−74,230 shares
Desktop Metal Inc~$5.4MSold out · 0.3% → 0.0%−1,104,871 shares
Lyell Immunopharma Inc~$3.2MSold out · 0.2% → 0.0%−5,865,125 shares
Verve Therapeutics Inc~$2.0MCut · 3.6% → 6.4%−180,597 shares
Kronos Bio Inc~$1.2MSold out · 0.1% → 0.0%−1,438,232 shares
Rani Therapeutics Hldgs Inc~$565,100Sold out · 0.0% → 0.0%−448,492 shares

Holdings

As of Jun 30, 2025. Changes are in shares against Mar 31, 2025, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Ast Spacemobile IncCOM CL A · shares 0% · price +105.5%	19.6%	12.9%	$417.9M	8.9M	0%	$46.73	$22.74	+105.5%	+$214.6M
2	Arm Holdings PlcSPONSORED ADS · shares 0% · price +51.5%	14.9%	13.3%	$317.1M	2.0M	0%	$161.74	$106.79	+51.5%	+$107.7M
3	Freshworks IncCLASS A COM · shares 0% · price +5.7%	11.3%	14.5%	$241.6M	16.2M	0%	$14.91	$14.11	+5.7%	+$13.0M
4	Planet Labs PbcCOM CL A · shares 0% · price +80.5%	9.1%	6.8%	$194.9M	31.9M	0%	$6.10	$3.38	+80.5%	+$86.9M
5	Revolution Medicines IncCOM · shares 0% · price +4.0%	7.1%	9.3%	$152.1M	4.1M	0%	$36.79	$35.36	+4.0%	+$5.9M
6	Metsera IncCOM · shares 0% · price +4.5%	6.6%	8.6%	$141.2M	5.0M	0%	$28.45	$27.22	+4.5%	+$6.1M
7	Verve Therapeutics IncCOM · shares −1.5% · price +145.7%	6.4%	3.6%	$136.7M	12.2M	−1.5%	$11.23	$4.57	+145.7%	+$81.0M
8	Gitlab IncCLASS A COM · shares 0% · price −4.0%	5.8%	8.1%	$122.9M	2.7M	0%	$45.11	$47.00	−4.0%	−$5.1M
9	Tempus AICL A · shares 0% · price +31.7%	4.6%	4.7%	$98.6M	1.6M	0%	$63.54	$48.24	+31.7%	+$23.7M
10	Dexcom IncCOM · shares 0% · price +27.8%	4.2%	4.5%	$90.5M	1.0M	0%	$87.29	$68.29	+27.8%	+$19.7M
11	UiPathCL A · shares 0% · price +24.3%	4.2%	4.6%	$90.0M	7.0M	0%	$12.80	$10.30	+24.3%	+$17.6M
12	Prime Medicine IncCOM · shares 0% · price +24.1%	1.7%	1.9%	$37.2M	15.1M	0%	$2.47	$1.99	+24.1%	+$7.2M
13	Maze Therapeutics IncCOM · shares 0% · price +11.4%	1.4%	1.7%	$29.6M	2.4M	0%	$12.27	$11.01	+11.4%	+$3.0M
14	Oscar Health IncCL A · shares 0% · price +63.5%	0.48%	0.40%	$10.3M	481,988	0%	$21.44	$13.11	+63.5%	+$4.0M
15	Sana Biotechnology IncCOM · shares 0% · price +62.5%	0.36%	0.30%	$7.7M	2.8M	0%	$2.73	$1.68	+62.5%	+$3.0M
16	Monte Rosa Therapeutics IncCOM · shares 0% · price −2.8%	0.31%	0.43%	$6.6M	1.5M	0%	$4.51	$4.64	−2.8%	−$190,322
17	Vera Therapeutics IncCL A · shares 0% · price −1.9%	0.27%	0.37%	$5.7M	241,264	0%	$23.56	$24.02	−1.9%	−$110,981
18	Beam Therapeutics IncCOM · shares 0% · price −12.9%	0.26%	0.40%	$5.5M	321,604	0%	$17.01	$19.53	−12.9%	−$810,442
19	Relay Therapeutics IncCOM · shares 0% · price +32.1%	0.25%	0.26%	$5.4M	1.6M	0%	$3.46	$2.62	+32.1%	+$1.3M
20	Dianthus Therapeutics IncCOM · shares 0% · price +2.7%	0.18%	0.24%	$3.9M	208,697	0%	$18.63	$18.14	+2.7%	+$102,261
21	Lyell Immunopharma IncCOM NEW · shares New	0.12%	—	$2.6M	293,256	New	$8.84	—	—	—
22	Spero Therapeutics IncCOM · shares 0% · price +302.8%	0.12%	0.04%	$2.6M	889,979	0%	$2.90	$0.720	+302.8%	+$1.9M
23	Foghorn Therapeutics IncCOM · shares 0% · price +28.8%	0.11%	0.12%	$2.4M	500,901	0%	$4.70	$3.65	+28.8%	+$525,946
24	Genedx Holdings CorpCOM · shares 0% · price +4.2%	0.10%	0.13%	$2.1M	22,711	0%	$92.31	$88.57	+4.2%	+$84,939
25	Autolus Therapeutics PlcSPON ADS · shares 0% · price +47.1%	0.07%	0.07%	$1.6M	698,262	0%	$2.28	$1.55	+47.1%	+$509,731
	Total · 36 positions	100%		$2.14B						+$593.0M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2025 to Q2 2025: 35 stocks held throughout, up $593.0M (+38.5%).

Ast Spacemobile Inc+$214.6M+105%
Arm Holdings Plc+$107.7M+51%
Planet Labs Pbc+$86.9M+80%
Verve Therapeutics Inc+$81.0M+146%
Tempus AI+$23.7M+32%
Barinthus Biotherapeutics Pl−$60,546−4%
Vera Therapeutics Inc−$110,981−2%
Monte Rosa Therapeutics Inc−$190,322−3%
Beam Therapeutics Inc−$810,442−13%
Gitlab Inc−$5.1M−4%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗